Legend Biotech
Presencia
Legend Biotech es una empresa que cotiza bajo el símbolo de cotización LEGN (US).
Ejecutivos
Ver el organigrama con sus 26 ejecutivos principales
Biografías más buscadas en Legend Biotech
- Ying Huang, Director, Chief Executive Officer and Chief Financial ...
- Frank Zhang, Chairman of the Board
- Philip Yau, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Legend Biotech.
Biotecnología
Legend Biotech tiene 2.274 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
- Nurix Therapeutics acaba de anunciar una recaudación de fondos de 175 millones de dólares. (publicado el 13 de abril de 2024).
- Nuvation Bio has announced the acquisition of AnHeart (publicado el 12 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Legend Biotech
- Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report – Legend BiotechBack ButtonSearch IconFilter Icon
- CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights – Legend BiotechBack ButtonSearch IconFilter Icon
- Newsroom - Legend Biotech
- Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results – Legend BiotechBack ButtonSearch IconFilter Icon
- Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) – Legend BiotechBac
- Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3 – Legend BiotechBack ButtonSearch IconFilter Icon
- Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) – Legend BiotechBac
- View more press releases Close
Redes sociales sobre Legend Biotech
- Legend Biotech en Wikipedia, Google News y Yahoo Finance
- Legend Biotech en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Ying Huang 
Llame a Legend Biotech al +1 173 ...
